3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
2
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
20
Carcinoma, Non-Small-Cell Lung
19
Pancreatic Neoplasms
17
Triple Negative Breast Neoplasms
16
Neoplasm Metastasis
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Neoplasms
5
Lung Neoplasms
4
Carcinoma
4
Neoplasms by Site
3
Adenocarcinoma
3
Pancreatic Diseases
2
Ovarian Neoplasms
2
Neoplasms by Histologic Type
2
Fallopian Tube Neoplasms
2
Endocrine System Diseases
2
Endocrine Gland Neoplasms
2
Digestive System Neoplasms
2
Digestive System Diseases
2
Carcinoma, Pancreatic Ductal
2
Carcinoma, Ductal, Breast
2
Vaccinia
1
Thromboembolism
1
Thoracic Neoplasms
1
Squamous Non-Small Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Peritoneal Neoplasms
1
Pancreatic cancer, adult
1
Interventions
Letrozole
5
Paclitaxel
4
atamestane
3
Toremifene
3
Tamoxifen
3
Cyclophosphamide
3
Estrogen Receptor Modulators
2
Epirubicin
2
Doxorubicin
2
Docetaxel
2
Carboplatin
2
Capecitabine
2
Aromatase Inhibitors
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
pertuzumab
1
ferric carboxymaltose
1
atezolizumab
1
Vinorelbine
1
Trastuzumab
1
TP protocol
1
Surgical Procedures, Operative
1
Radiotherapy
1
Medroxyprogesterone
1
Fulvestrant
1
Fluorouracil
1
Estrogens, Conjugated (USP)
1
Cisplatin
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma, Ductal, Breast
×
130-nm albumin-bound paclitaxel
×
Clear all
NCT02620280
2024-03-06
NeoTRIPaPDL1
Fondazione Michelangelo
Phase 3
Completed
278 enrolled
NCT01583426
2020-08-06
GeparSepto
GBG Forschungs GmbH
Phase 3
Completed
1,229 enrolled